TRXE-002-01 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

12,757 results for “TRXE-002-01”

Kazia Therapeutics Sells Cantrixil Intellectual Property Rights to Vivesto for $1 Million

PleoPharma Doses First Patient in Pivotal Phase 3 Trial of PP-01 for Cannabis Withdrawal, Presents Phase 2 Data Showing 43% Reduction in Irritability

Cothera Bioscience's PC-002 Receives FDA Fast Track for Burkitt Lymphoma

Pierre Fabre's PFL-002/VERT-002 Enters Phase I/II Trial for NSCLC with MET Alterations

Pierre Fabre's PFL-002/VERT-002 Enters Phase I/II Trial for NSCLC with MET Alterations

Loyal's LOY-002 Receives FDA's RXE Acceptance for Canine Lifespan Extension

Aer Therapeutics Doses First Patient in Phase 2 Trial of Fexlamose for COPD

PleoPharma's PP-01 Shows Significant Efficacy in Phase 2b Trial for Cannabis Withdrawal Syndrome

PDS Biotech's Versamune® HPV Plus Pembrolizumab Shows Promising Results in HPV16-Positive Head and Neck Cancer

Kiromic BioPharma's Deltacel Shows Promise in NSCLC Trial, Moves to Dose Expansion

Page 1 of 138